{"filing":{"accession_number":"0001493152-26-041877","cik":"0001412486","ticker":"COCP","company_name":"Cocrystal Pharma, Inc.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226041877/form8-k.htm"},"events":[{"id":32208,"run_id":29589,"accession_number":"0001493152-26-041877","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses completion of the last-subject-dosed milestone in a Phase 1b clinical trial for CDI-988, a novel antiviral candidate for norovirus. This represents a material operational and clinical development milestone for a clinical-stage biotech company, with preliminary efficacy results expected in late 2026 or early 2027. While this is a positive clinical progress event rather than a specific named event type (earnings, M\u0026A, impairment, etc.), it is clearly material to investors' assessment of the company's pipeline advancement and would affect the total mix of information available.","company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":35321,"accession_number":"0001493152-26-041877","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses completion of the last-subject-dosed milestone in a Phase 1b clinical trial for CDI-988, a novel antiviral candidate for norovirus. This represents a material operational and clinical development milestone for a clinical-stage biotech company, with preliminary efficacy results expected in late 2026 or early 2027. While this is a positive clinical progress event rather than a specific named event type (earnings, M\u0026A, impairment, etc.), it is clearly material to investors' assessment of the company's pipeline advancement and would affect the total mix of information available.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T12:04:47.556801+00:00","company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","filing_date":"2026-09-09"}]}